Innovus Pharmaceuticals Inc. (fka INNV)

[bfabrico]

Currently, I am not seeing any potential of this crossing $0.30-$0.40 range. We are already valued at $21M currently, with no profits and projected revenues of $10M-$15M. Blue Apron, the meal kit service with couple of hundred million in sales, its IPO values it at 1.6 times revenue. Ecommerce companies are valued at 3.1 times revenues in general. Why would we be valued at 2X our revenues? Even this valuation is not sustainable based on current revenues.

Now, if there is no further dilution and if we have double - triple the revenue by next year, we would be in this range, otherwise not. I am still evaluating options how that would be possible without dilution. I had shared this perspective on Investorhub sometime ago

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=131785278

I have poured heavily in this stock, but I will be carefully evaluating the next couple of months here. The constant issue that worries me is that none of the products in our current pipeline have decent reviews on Amazon. I have spent some time reading through those and the responses from users (there are hundreds out there) that has shaken my confidence in them. A lot of users have given the products flat out 1 stars. Makes me question on what basis is Damaj saying that Zestra or Sensum + or Vesele will be big winners if the current set of customers is completely unhappy with them